Incyte Corporation (INCY) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $100.09
• Market Cap: $19.90B
• P/E Ratio: 15.60
• EPS: $6.41
• 52-Week High: $112.29
• 52-Week Low: $53.56

Market Sentiment

Incyte Corporation currently has a Bullish sentiment score of 0.16.

About Incyte Corporation

Incyte Corporation, based in Wilmington, Delaware, is a leading biopharmaceutical firm specializing in the development of innovative therapies for oncology and other critical diseases. Founded in 1991, the company has established a strong commercial presence with its flagship product, Jakafi, which is used to treat myelofibrosis and polycythemia vera, while also advancing a diverse pipeline of candidates targeting various cancer types. Incyte's dedication to precision medicine and its collabo...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Incyte Corporation and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does INCY pay dividends?

Incyte Corporation (INCY) does not currently pay a regular dividend.

What is INCY's P/E ratio?

Incyte Corporation has a price-to-earnings (P/E) ratio of 15.60.

What is INCY's market cap?

Incyte Corporation (INCY) has a market capitalization of $19.90B with a current stock price of $100.09.